Literature DB >> 26983026

Comparative Renal Toxicopathology of Antisense Oligonucleotides.

Jeffery A Engelhardt1.   

Abstract

This review summarizes the current understanding of nephrotoxicity related to the administration of therapeutic oligonucleotides, particularly those with 2'-methoxy-ethyl (2'-MOE) modifications. To best understand the effects of antisense oligonucleotides (ASOs) on the kidney, the reader should have a general understanding of renal microanatomy, physiology, and general mechanisms related to toxicity, so a short review is presented. Preclinical-clinical correlates are also discussed. Collectively, the data for PS ODN and 2'-MOE-modified ASOs have shown the laboratory animal species utilized in toxicology studies generally overpredict renal effects of these agents. As such, 2'-MOE ASOs do not appear to pose as much of a risk to patients as the preclinical data would suggest. This observation has been confirmed so far in clinical investigations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26983026     DOI: 10.1089/nat.2015.0598

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  13 in total

1.  Oligonucleotide therapies for disorders of the nervous system.

Authors:  Olga Khorkova; Claes Wahlestedt
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

2.  Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation.

Authors:  John H Beigel; Jocelyn Voell; Paula Muñoz; Parag Kumar; Kristina M Brooks; Jianbo Zhang; Patrick Iversen; Alison Heald; Michael Wong; Richard T Davey
Journal:  Br J Clin Pharmacol       Date:  2017-09-22       Impact factor: 4.335

3.  Quantitative Measurement of Cytosolic and Nuclear Penetration of Oligonucleotide Therapeutics.

Authors:  Kirsten Deprey; Nefeli Batistatou; Marjoke F Debets; Jack Godfrey; Kirstin B VanderWall; Rebecca R Miles; Livia Shehaj; Jiaxing Guo; Amy Andreucci; Pachamuthu Kandasamy; Genliang Lu; Mamoru Shimizu; Chandra Vargeese; Joshua A Kritzer
Journal:  ACS Chem Biol       Date:  2022-01-15       Impact factor: 4.634

4.  Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial.

Authors:  Kathryn R Wagner; Nancy L Kuntz; Erica Koenig; Lilly East; Sameer Upadhyay; Baoguang Han; Perry B Shieh
Journal:  Muscle Nerve       Date:  2021-06-29       Impact factor: 3.852

5.  Therapy with 2'-O-Me Phosphorothioate Antisense Oligonucleotides Causes Reversible Proteinuria by Inhibiting Renal Protein Reabsorption.

Authors:  Manoe J Janssen; Tom T G Nieskens; Tessa A M Steevels; Pedro Caetano-Pinto; Dirk den Braanker; Melissa Mulder; Yolanda Ponstein; Shaun Jones; Rosalinde Masereeuw; Cathaline den Besten; Martijn J Wilmer
Journal:  Mol Ther Nucleic Acids       Date:  2019-09-06       Impact factor: 8.886

Review 6.  The glomerular filtration barrier: a structural target for novel kidney therapies.

Authors:  Ilse S Daehn; Jeremy S Duffield
Journal:  Nat Rev Drug Discov       Date:  2021-07-14       Impact factor: 84.694

Review 7.  Delivery is key: lessons learnt from developing splice-switching antisense therapies.

Authors:  Caroline Godfrey; Lourdes R Desviat; Bård Smedsrød; France Piétri-Rouxel; Michela A Denti; Petra Disterer; Stéphanie Lorain; Gisela Nogales-Gadea; Valentina Sardone; Rayan Anwar; Samir El Andaloussi; Taavi Lehto; Bernard Khoo; Camilla Brolin; Willeke Mc van Roon-Mom; Aurélie Goyenvalle; Annemieke Aartsma-Rus; Virginia Arechavala-Gomeza
Journal:  EMBO Mol Med       Date:  2017-05       Impact factor: 12.137

8.  Monitoring and manipulating cellular crosstalk during kidney fibrosis inside a 3D in vitro co-culture.

Authors:  Bramasta Nugraha; Manuel A Mohr; Aaron Ponti; Maximilian Y Emmert; Franziska Weibel; Simon P Hoerstrup; Solange Moll; Ulrich Certa; Marco Prunotto; Periklis Pantazis
Journal:  Sci Rep       Date:  2017-11-03       Impact factor: 4.379

Review 9.  Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.

Authors:  Qing Li
Journal:  Yonsei Med J       Date:  2020-04       Impact factor: 2.759

Review 10.  Oligonucleotide-Based Therapies for Renal Diseases.

Authors:  Fernando Cartón-García; Cassondra Jeanette Saande; Daniel Meraviglia-Crivelli; Rafael Aldabe; Fernando Pastor
Journal:  Biomedicines       Date:  2021-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.